Academic literature on the topic 'Contraceptives'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Contraceptives.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Contraceptives"
David, Luiza Ortiz, and Sheldon Rodrigo Botogoski. "SARC e LARC: grau de conhecimento e frequência de uso em complexo hospitalar de referência no Paraná / SARC and LARC: degree of knowledge and frequency of use in a reference hospital complex in Paraná." Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo 66, no. 1u (May 26, 2021): 1. http://dx.doi.org/10.26432/1809-3019.2021.66.016.
Full textAkter, Dr Aliza, Dr Umme Shaila, Dr Rashed Md Sharif, and Dr Sadia Israt Zaman. "The Relationship between Hormonal Contraceptives and Metabolic Syndrome." Scholars Journal of Applied Medical Sciences 10, no. 3 (March 30, 2022): 375–79. http://dx.doi.org/10.36347/sjams.2022.v10i03.017.
Full textLima, Adman Câmara Soares, Larissa Castelo Guedes Martins, Marcos Venícios de Oliveira Lopes, Thelma Leite de Araújo, Francisca Elisângela Teixeira Lima, Priscila de Souza Aquino, and Escolástica Rejane Ferreira Moura. "Influence of hormonal contraceptives and the occurrence of stroke: integrative review." Revista Brasileira de Enfermagem 70, no. 3 (June 2017): 647–55. http://dx.doi.org/10.1590/0034-7167-2016-0056.
Full textAnis, Wahyul, Erni Rosita Dewi, Renata Alya Ulhaq, Shrimarti Rukmini Devy, Budi Prasetyo, Diah Indriani, and Kasiati. "Use of contraceptives in a high-income population: a cross-sectional study in Indonesia." British Journal of Midwifery 31, no. 9 (September 2, 2023): 496–501. http://dx.doi.org/10.12968/bjom.2023.31.9.496.
Full textGunardi, Eka Rusdianto, Denny Khusen, and Kevin Winston. "The Role of Contraception in the Past, Present and Future." Journal Of The Indonesian Medical Association 68, no. 8 (September 25, 2019): 395–400. http://dx.doi.org/10.47830/jinma-vol.68.8-2018-50.
Full textTshitenge, S. T., K. Nlisi, V. Setlhare, and R. Ogundipe. "Knowledge, attitudes and practice of healthcare providers regarding contraceptive use in adolescence in Mahalapye, Botswana." South African Family Practice 60, no. 6 (November 30, 2018): 39. http://dx.doi.org/10.4102/safp.v60i6.4928.
Full textJalalvandi, Esmat, Hafez Jafari, Christiani A. Amorim, Denise Freitas Siqueira Petri, Lei Nie, and Amin Shavandi. "Vaginal Administration of Contraceptives." Scientia Pharmaceutica 89, no. 1 (December 25, 2020): 3. http://dx.doi.org/10.3390/scipharm89010003.
Full textWilliams, Jennifer S., and Maureen J. MacDonald. "Influence of hormonal contraceptives on peripheral vascular function and structure in premenopausal females: a review." American Journal of Physiology-Heart and Circulatory Physiology 320, no. 1 (January 1, 2021): H77—H89. http://dx.doi.org/10.1152/ajpheart.00614.2020.
Full textCano Andrade, Ricardo Andres. "Legal-dogmatic controversies between civil law and criminal law: the case of the exercise of the right of possession in Colombia." Sociology International Journal 7, no. 4 (August 7, 2023): 193–201. http://dx.doi.org/10.15406/sij.2023.07.00343.
Full textMbihbiih, Niying Roger. "Perception variation on contraceptive use in the Bamenda and Buea communities in Cameroon." Sociology International Journal 7, no. 4 (August 14, 2023): 203–9. http://dx.doi.org/10.15406/sij.2023.07.00344.
Full textDissertations / Theses on the topic "Contraceptives"
Ferreira, Jéssica Mayra 1988. "Razões para a troca de diferentes contraceptivos para contraceptivos reversíveis de longa duração entre mulheres brasileiras = Reasons for Brazilian women to switch from different contraceptives to long-acting reversible contraceptives." [s.n.], 2013. http://repositorio.unicamp.br/jspui/handle/REPOSIP/312837.
Full textDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas
Made available in DSpace on 2018-08-24T12:55:50Z (GMT). No. of bitstreams: 1 Ferreira_JessicaMayra_M.pdf: 1683051 bytes, checksum: d85c69881bfcbb72838041d2f09bb2c1 (MD5) Previous issue date: 2013
Resumo: Objetivos: conhecer as razões referidas pelas mulheres que trocaram seus métodos anticonceptivos (MAC) para um método contraceptivo reversível de longa duração (Long Acting Reversible Contraceptives ¿ LARC) e avaliar sua satisfação através da taxa de continuação. Métodos: Mulheres entre 18 e 50 anos de idade usando diferentes MACs que desejavam mudar para um LARC responderam a um questionário abrangendo suas motivações para trocarem seus atuais métodos. O tamanho amostral foi calculado em 1.040 mulheres. O desempenho clínico e a taxa de continuação foram avaliados por tabela de vida até um ano após o início do uso do LARC. A data limite para análise foi 23 de maio de 2013. Resultados: Do total de 1.167 entrevistadas, foram avaliados os dados de 1154 mulheres. A principal razão pessoal para a troca de contraceptivos foi o medo de engravidar enquanto que as principais razões médicas foram náusea e vômito e anormalidades no fluxo menstrual. Nenhuma gravidez ocorreu durante o uso dos LARCs e as principais causas para descontinuação foram expulsão do DIU ou SIU-LNG e a decisão de realizar esterilização entre as usuárias de implante. A taxa de continuação foi aproximadamente 95,0/100 mulheres/ano para os três métodos. Conclusões: A maioria das mulheres escolheu um LARC por ser mais prático e mais seguro e, após um ano, grande parte das mulheres continuou utilizando o método escolhido
Abstract: Objectives: To assess the main reasons for switching from methods requiring daily or monthly compliance to a Long Acting Reversible Contraceptive (LARC) method within a Brazilian cohort and to evaluate their satisfaction. Methods: Women of 18-50 years of age in use of different contraceptives and wishing to switch to a LARC method answered a questionnaire regarding their motivations for switching from their current contraceptive. Continuation rates were evaluated one year after method initiation. Sample size was calculated at 1,040 women. Clinical performance was evaluated by life table analysis. The cut-off date for analysis was May 23, 2013. Results: Overall, 1,167 women were interviewed; however, after one year of use, the medical records of 1,154 women were available for review. The main personal reason for switching, as reported by women, was "fear of becoming pregnant" while the medical reasons were nausea and vomiting and unscheduled bleeding. No pregnancies occurred during LARC use and the main reasons for discontinuation were expulsion (in the case of the IUD and LNG-IUS), and a decision to undergo surgical sterilization (in the case of the etonogestrel-releasing implant). Continuation rate was approximately 95.0/100 women/year for the three methods. Conclusions: Most women chose a LARC method for its safety and for practical reasons, and after one year of use most women continued with the method
Mestrado
Fisiopatologia Ginecológica
Mestra em Ciências da Saúde
Ackermann, Camila Louise [UNESP]. "Uso do acetato de deslorelina como contraceptivo em gatos domésticos." Universidade Estadual Paulista (UNESP), 2012. http://hdl.handle.net/11449/98164.
Full textFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
O objetivo do presente estudo foi avaliar os efeitos do acetato de deslorelina como contraceptivo em felinos domésticos. Foram utilizados 15 gatos domésticos (10 fêmeas e 5 machos). As fêmeas foram acompanhadas através de citologias vaginais (CV), observação do comportamento sexual a cada 72 horas e dosagem de progesterona plasmática a cada 7dias. Quando em interestro/diestro as gatas foram submetidas à associação anestésica e um implante de acetato de deslorelina (Suprelorin® Peptech Animal Health Pty Limited, Austrália; 4,7 mg/animal) foi aplicado, permanecendo por 90 dias depois. Dez dias após a retirada do implante o estro e a ovulação foram induzidos com eCG e Hcg; três dias após as fêmeas foram submetidas à ovariosalpingohisterectomia. As tubas uterinas e útero foram lavados e o liquido recuperado foi observado para identificação e contagem de possíveis oócitos. Os oócitos foram isolados e corados para avaliação da viabilidade, os corpos lúteos quantificados e o cálculo da taxa de recuperação oocitária foi realizado.. Os ovários e útero foram avaliados quanto à histologia. Alterações histológicas foram descritas e as concentrações plasmáticas de progesterona foram submetidas a teste de normalidade e posteriormente submetidas ao Teste de Kolmogorov-Smirnov. Os demais resultados estão descritos em forma de média e desvio padrão. Os machos foram submetidos a duas avaliações andrológicas (M1 e M2) sempre precedidas de anestesia geral, imediatamente após a M2, um implante de acetato de deslorelina (Suprelorin® Peptech Animal Health Pty Limited, Austrália; 4,7 mg/animal) foi aplicado em cada gato. Após o inicio do tratamento foram realizadas mais três avaliações andrológicas (M3, M4 e M5) com intervalo de 30 dias. Após a M5, os implantes foram retirados e uma hemi orquiectomia realizada. Mais duas avaliações...
This study aimed evaluates the deslorelin acetate effects as a contraceptive in domestic felids. Fifteen domestic cats (10 females and 5 males) were used. The females were evaluated trough vaginal cytology (VC) and sexual behavior every 72 hours, and progesterone plasmatic concentration every 7 days. When in interestrous/diestrous the queens were submitted to an anesthetic protocol and receive one deslorelin acetate implant (Suprelorin® Peptech Animal Health Pty Limited, Australia; 4.7 mg/animal), remaining in treatment for 90 days. Teen days after the implant removal the estrous and ovulation were induced with eCG and hCG; three days after, all females were submitted to surgical castration. The oviduts and uterus were washed and the recovered liquid was observed for oocytes identification and count. The recovered oocytes were isolated and stained for viability evaluation, the corpus luteum were quantified and the oocyte recovery tax was calculated. Histologic evaluation was carried out in the ovary and uterus. The histologic evaluations were described and progesterone plasmatic concentration were submitted to Kolmogorov-Smirnov test. The remaining results were described as mean and standard deviation. Males were submitted to two andrological evaluations (M1 and M2), always preceded by anesthetic protocol. Immediately after M2, every cat receives one deslorelin acetate implant (Suprelorin® Peptech Animal Health Pty Limited, Australia; 4.7 mg/animal). After contraceptive treatment beginning, three andrological evaluations were conducted (M3, M4, and M5) with 30 days interval. After M5, the implants were removed and a hemiorquiectomy was performed. Other two andrological evaluations were performed (M6 and M7) with 30 days interval and at M7 the remaining testicle were removed. The testicles were submitted ...(Complete abstract click electronic access below)
Ackermann, Camila Louise. "Uso do acetato de deslorelina como contraceptivo em gatos domésticos /." Botucatu : [s.n.], 2012. http://hdl.handle.net/11449/98164.
Full textBanca: Carlos Roberto Teixeira
Banca: Marcelo Alcindo de Barros Vaz Guimarães
Resumo: O objetivo do presente estudo foi avaliar os efeitos do acetato de deslorelina como contraceptivo em felinos domésticos. Foram utilizados 15 gatos domésticos (10 fêmeas e 5 machos). As fêmeas foram acompanhadas através de citologias vaginais (CV), observação do comportamento sexual a cada 72 horas e dosagem de progesterona plasmática a cada 7dias. Quando em interestro/diestro as gatas foram submetidas à associação anestésica e um implante de acetato de deslorelina (Suprelorin® Peptech Animal Health Pty Limited, Austrália; 4,7 mg/animal) foi aplicado, permanecendo por 90 dias depois. Dez dias após a retirada do implante o estro e a ovulação foram induzidos com eCG e Hcg; três dias após as fêmeas foram submetidas à ovariosalpingohisterectomia. As tubas uterinas e útero foram lavados e o liquido recuperado foi observado para identificação e contagem de possíveis oócitos. Os oócitos foram isolados e corados para avaliação da viabilidade, os corpos lúteos quantificados e o cálculo da taxa de recuperação oocitária foi realizado.. Os ovários e útero foram avaliados quanto à histologia. Alterações histológicas foram descritas e as concentrações plasmáticas de progesterona foram submetidas a teste de normalidade e posteriormente submetidas ao Teste de Kolmogorov-Smirnov. Os demais resultados estão descritos em forma de média e desvio padrão. Os machos foram submetidos a duas avaliações andrológicas (M1 e M2) sempre precedidas de anestesia geral, imediatamente após a M2, um implante de acetato de deslorelina (Suprelorin® Peptech Animal Health Pty Limited, Austrália; 4,7 mg/animal) foi aplicado em cada gato. Após o inicio do tratamento foram realizadas mais três avaliações andrológicas (M3, M4 e M5) com intervalo de 30 dias. Após a M5, os implantes foram retirados e uma hemi orquiectomia realizada. Mais duas avaliações ...(Resumo completo, clicar acesso eletrônico abaixo)
Abstract: This study aimed evaluates the deslorelin acetate effects as a contraceptive in domestic felids. Fifteen domestic cats (10 females and 5 males) were used. The females were evaluated trough vaginal cytology (VC) and sexual behavior every 72 hours, and progesterone plasmatic concentration every 7 days. When in interestrous/diestrous the queens were submitted to an anesthetic protocol and receive one deslorelin acetate implant (Suprelorin® Peptech Animal Health Pty Limited, Australia; 4.7 mg/animal), remaining in treatment for 90 days. Teen days after the implant removal the estrous and ovulation were induced with eCG and hCG; three days after, all females were submitted to surgical castration. The oviduts and uterus were washed and the recovered liquid was observed for oocytes identification and count. The recovered oocytes were isolated and stained for viability evaluation, the corpus luteum were quantified and the oocyte recovery tax was calculated. Histologic evaluation was carried out in the ovary and uterus. The histologic evaluations were described and progesterone plasmatic concentration were submitted to Kolmogorov-Smirnov test. The remaining results were described as mean and standard deviation. Males were submitted to two andrological evaluations (M1 and M2), always preceded by anesthetic protocol. Immediately after M2, every cat receives one deslorelin acetate implant (Suprelorin® Peptech Animal Health Pty Limited, Australia; 4.7 mg/animal). After contraceptive treatment beginning, three andrological evaluations were conducted (M3, M4, and M5) with 30 days interval. After M5, the implants were removed and a hemiorquiectomy was performed. Other two andrological evaluations were performed (M6 and M7) with 30 days interval and at M7 the remaining testicle were removed. The testicles were submitted ...(Complete abstract click electronic access below)
Mestre
Nyeko, Moini Brian Anyau. "Hormonal Contraceptives for men." Thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2018. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-422360.
Full textKauki, Tom. "Quality of the combined oral contraceptive pill (0.15mg levonorgestrel and 0.03mg ethinylestradiol) in the private retail pharmacies of Nyeri Town, Kenya. Results from a postmarket quality study." University of the Western Cape, 2015. http://hdl.handle.net/11394/4691.
Full textBackground: The effectiveness of the combined oral contraceptive pill as a family planning method is dependent on its quality. The quality of medicines on the healthcare market is established through postmarket quality studies. Methods: The quality of the combined oral contraceptive pill was established through the collection of samples from 17 (62%) private retail pharmacies in the Nyeri town of Kenya. Their quality was then determined through the assay of content of levonorgestrel and ethinylestradiol and the levonorgestrel dissolution test at the National Quality Control Laboratory. Findings: 13 of the 17 pharmacies were licensed with the Pharmacy and Poisons Board while 4 were unlicensed. Femiplan® was available in all the 17 pharmacies while Microgynon® was available in only 4 pharmacies. 17 samples of Femiplan® and 4 samples of Microgynon® were collected. None of the samples was counterfeit or falsely labeled. All the samples passed the assay of content of levonorgestrel and ethinylestradiol and the levonorgestrel dissolution test. Conclusion: Notwithstanding the fact this study provides a snapshot in time, it is reasonable to conclude that the combined oral contraceptive pill (0.15mg levonorgestrel and 0.03mg ethinylestradiol) in the Nyeri town of Kenya private retail pharmacies is of the right quality with respect to the quality tests of assay of content of levonorgestrel and ethinylestradiol and the levonorgestrel dissolution test.
Mothogoane, Kagiso Andronicca. "Challenges faced by female teenagers in accessing contraceptives at Bylodrift Clinic, Malatane Village, Capricorn District of Limpopo Province." Thesis, University of Limpopo, 2018. http://hdl.handle.net/10386/2328.
Full textThe study sought to provide deeper understanding on access to contraceptives by female teenagers. The aim of this study was to explore the challenges faced by female teenagers in accessing contraceptives at Byldrift Clinic, Malatane Village, Capricorn District of Limpopo Province. Qualitative research method was applied in the study. The study utilised case study research design. Purposive sampling was used to select participants. Face to face interviews were conducted with ten (10) female teenagers. The age of participants ranges from 15 years to 19 years. Thematic Analysis was used to analyse data. The negative attitude of healthcare providers was cited as a challenge for teenagers accessing contraceptives, however other participants cited positive attitude of healthcare providers. The experience of side effects, parents and partners were cited as major challenges experienced while using contraceptives. The problem of inaccessibility remains a challenge in public health facilities; participants reported long waiting times, long distance to get to the clinic, shortage of staff, lack of confidentiality and lack of proper infrastructure. Most participants indicated that they discuss contraception with their peers, therefore peer influence remains an influential factor in accessing contraceptives. The study recommended that healthcare providers should give the effectiveness rate of the contraceptive method and ways to manage side effects, health facilities need to be more user friendly and that operating hours should be convenient to teenagers who are still schooling. This is evident that young women face challenges in accessing contraceptives. Keywords: Access, challenge, contraceptives, teenagers
Hedner, Benjamin, Karl Irgens Eliasson, and Pär Isaksson. "Factors affecting Women when choosing Contraceptives." Thesis, Karlstad University, Karlstad University, 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-1183.
Full textAmaral, Douglas Sousa. "Avaliação de formulações contraceptivas por parâmetros hemostáticos, vasoativos e inflamatórios em cultura de células endoteliais humanas." Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/60/60135/tde-25092015-143858/.
Full textCombined oral contraceptives (COCs) are widely used and well accepted to provide contraception. It\'s estimated that over 100 million women around the world make use of this contraceptive method. Although contraception is achieved, these users are predisposed to developing venous thromboembolism or arterial and development of atherosclerosis due to the change caused by the hemostatic dose of estrogen and progestin type used in the formulations. In order to get a said formulation \"correct\" and hoping that the adverse effects that may occur at the expense of the contraceptive formulation composition are minimized, the literature indicates a contraceptive recently launched, whose composition contains Estradiol valerate (called natural estrogen by the pharmaceutical industry) as estrogen component and the Dienogest as synthetic progesterone, integrating the group of so classified new progestins. OBJECTIVE: Within the context that we present above, the research project aimed to evaluate two contraceptive formulations, through a comparative experimental study, where as the control group used the classic Levonorgestrel (LVG) and ethinylestradiol (EE), to compare it with the new progestin released in Brazil in 2011, composed of Dienogest (DNG) and estradiol valerate (17? Estradiol - active metabolite) - both alone and in combination medications, represented by MIX I (LVG plus EE) and MIX II (DNG plus 17?), respectively. \'Cause little is known about the effects of the progestogen on the new vasoactive factors, hemostatic and inflammatory proposed here work with cultured endothelial cells derived from human umbilical cord stimulus them with LPS inflammatory agent and / or TNF? to further quantitate the following factors: HUVEC (Human Umbilical Vein Endothelial Cell) - adhesion molecules VCAM-I, ICAM-I and E-selectin (supernatant and cell surface); endothelium-derived vasoactive factors (NO, PGE2 and Endothelin ET-1 - culture supernatant) and pro-inflammatory cytokines as IL-1? and IL-6 in the supernatant. HAEC (Human Arterial Endothelial Cell): Tissue factor on primary cell culture of umbilical cord artery. The drugs reduced the expression of adhesion molecules in the supernatant and the cell surface reduced the production of endothelium-derived vasoactive factors, regulated the production of cytokines proinflammatory and also reduced the expression of tissue factor, preventive and therapeutic way. The mixture of contraceptives represented by MIX MIX I and II showed significant differences when compared to the other study groups and MIX II showed greater effectiveness in reducing some factors studied here, giving an endothelial protection. Thus, we can conclude that the new progestogen released in Brazil showed antithrombotic effects and anti-inflammatory, to reduce significantly the levels of adhesion molecules, vasoactive factors, proinflammatory factors and hemostatic factor.
Ezeanolue, Echezona E., Juliet Iwelunmor, Ibitola Asaolu, Michael C. Obiefune, Chinenye O. Ezeanolue, Alice Osuji, Amaka G. Ogidi, et al. "Impact of male partner's awareness and support for contraceptives on female intent to use contraceptives in southeast Nigeria." BioMed Central Ltd, 2015. http://hdl.handle.net/10150/610299.
Full textDallman, Rebecca. "Disparities in the Use of Emergency Contraceptives." VCU Scholars Compass, 2007. http://hdl.handle.net/10156/2056.
Full textBooks on the topic "Contraceptives"
(Organization), Family Health International. Oral contraceptives: Contraceptive technology. Research Triangle Park, NC: Family Health International, 1996.
Find full textRetailing, Corporate Intelligence on, ed. Contraceptives. London: CIR, 1998.
Find full textGroup, Mintel International, ed. Contraceptives. London: Mintel International Group, 1999.
Find full textHealth, Botswana Ministry of, ed. Managing family planning commodities and drugs in Botswana. [Gaborone] Botswana: Ministry of Health, 1989.
Find full textKleinman, R. L. Directory of hormonal contraceptives. 3rd ed. London: International Planned Parenthood Federation, 1996.
Find full textWillis, Judith. Comparing contraceptives. [Rockville, Md: Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Office of Public Affairs (5600 Fishers Lane, Rockville 20857)], 1991.
Find full textAffandi, Biran. Implantable contraceptives. Jakarta: National Family Planning Coordinating Board, 1991.
Find full textWillis, Judith. Comparing contraceptives. [Rockville, Md: Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Office of Public Affairs, 1989.
Find full textK, Sood S. Herbal contraceptives. Dehradun: International Book Distributors, 2011.
Find full textWillis, Judith. Comparing contraceptives. [Rockville, Md: Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Office of Public Affairs (5600 Fishers Lane, Rockville 20857)], 1991.
Find full textBook chapters on the topic "Contraceptives"
Gudermann, Thomas. "Contraceptives." In Encyclopedia of Molecular Pharmacology, 1–9. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-21573-6_43-1.
Full textGudermann, Thomas. "Contraceptives." In Encyclopedia of Molecular Pharmacology, 483–90. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-57401-7_43.
Full textShoupe, Donna. "Injectable Contraceptives and Contraceptive Vaginal Rings." In Clinical Perspectives in Obstetrics and Gynecology, 144–57. New York, NY: Springer New York, 1993. http://dx.doi.org/10.1007/978-1-4612-2730-4_13.
Full textd’Arcangues, Catherine, and Rachel C. Snow. "Injectable Contraceptives." In Fertility Control — Update and Trends, 121–49. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-86696-8_6.
Full textNelson, Anita L., and Jennefer Russo. "Barrier Contraceptives." In The Handbook of Contraception, 181–202. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-20185-6_11.
Full textNatavio, Melissa F. "Emergency Contraceptives." In The Handbook of Contraception, 203–13. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-20185-6_12.
Full textShoupe, Donna. "Barrier Contraceptives." In The Handbook of Contraception, 147–77. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1007/978-1-59745-150-5_10.
Full textShoupe, Donna, and Daniel R. Mishell. "Oral Contraceptives." In The Handbook of Contraception, 13–43. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1007/978-1-59745-150-5_2.
Full textShoupe, Donna. "Oral Contraceptives." In The Handbook of Contraception, 45–66. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1007/978-1-59745-150-5_3.
Full textSchickler, Robyn, and Jasmine Patel. "Barrier Contraceptives." In The Handbook of Contraception, 163–81. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-46391-5_9.
Full textConference papers on the topic "Contraceptives"
Gayatri, Maria. "The Use of Modern Contraceptives among Poor Women in Urban Areas in Indonesia." In The 7th International Conference on Public Health 2020. Masters Program in Public Health, Universitas Sebelas Maret, 2020. http://dx.doi.org/10.26911/the7thicph.03.27.
Full textFarag, A. M., S. F. Bottoms, E. F. Mammen, M. Hosni, and A. Ali. "EFFECT OF ORAL CONTRACEPTIVES ON HEMOSTASIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644283.
Full textAfriyanti, Neta, Eti Poncorini Pamungkasari, and Hanung Prasetya. "The Effect of Hormonal Contraceptive Use on the Risk of Depression in Women of Reproductive Age: Evidence from Gunungkidul, Yogyakarta." In The 7th International Conference on Public Health 2020. Masters Program in Public Health, Universitas Sebelas Maret, 2020. http://dx.doi.org/10.26911/the7thicph.03.121.
Full textMendoza, MD Molina, C. Palomar Fernandez, C. Perez Menénedez-Conde, B. Montero Llorente, L. García Basas, and T. Bermejo Vicedo. "PS-072 Oral contraceptives and risk of thromboembolic events." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.578.
Full textHurst, Noémie, Matthias Pellek, Patricia N. Sidharta, and Jasper Dingemanse. "Pharmacokinetics and safety of concomitant macitentan and hormonal contraceptives." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa2111.
Full textKulik, Marco Antonio, Rosa Maria Eid Weiler, Danilo Rodrigues de Oliveira, Juliana Teixeira, and Maria Sylvia de Souza Vitalle. "GENGIVAL BLEEDING IN ADOLESCENTS WITH USE OF ORAL CONTRACEPTIVES." In IV International Symposium Adolescence(s) and II Education Forum. Universidade Federal de São Paulo, 2018. http://dx.doi.org/10.22388/2525-5894.2018.0031.
Full textNingrum, Sri Setiyo, Dono Indarto, and Mahendra Wijaya. "EMPLOYMENT STATUS, FAMILY INCOME, CONTRACEPTIVE AVAILABILITY, AND THEIR EFFECTS ON THE USE OF LONG TERM CONTRACEPTIVES IN SUKOHARJO, CENTRAL JAVA." In THE 2ND INTERNATIONAL CONFERENCE ON PUBLIC HEALTH. Masters Program in Public Health, Sebelas Maret University, 2017. http://dx.doi.org/10.26911/theicph.2017.127.
Full textSatriyandari, Yekti, Yushe Quasimah, and Yuliana Umrotun. "The Use of Contraceptives in Commercial Sex Workers in Yogyakarta." In International Conference on Health and Medical Sciences (AHMS 2020). Paris, France: Atlantis Press, 2021. http://dx.doi.org/10.2991/ahsr.k.210127.033.
Full textMachin, S. J., I. J. Mackie, K. Walshe, and M. D. Gillmer. "HAEMOSTATIC CHANGES INDUCED BY TWO LOW DOSE TRIPHASIC ORAL CONTRACEPTIVES." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643825.
Full textSilva, Elisangela Da. "TROMBOSE VENOSA PROFUNDA EM MULHERES PELO USO DE CONTRACEPTIVOS ORAIS: UMA REVISÃO NARRATIVA." In II Congresso Brasileiro de Hematologia Clínico-laboratorial On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/hematoclil/39.
Full textReports on the topic "Contraceptives"
Kelsey, Jennifer L. Oral Contraceptives and Bone Health in Female Runners. Fort Belvoir, VA: Defense Technical Information Center, October 2004. http://dx.doi.org/10.21236/ada435728.
Full textKelsey, Jennifer L. Oral Contraceptives and Bone Health in Female Runners. Fort Belvoir, VA: Defense Technical Information Center, October 2005. http://dx.doi.org/10.21236/ada443584.
Full textKelsey, Jennifer L. Oral Contraceptives and Bone Health in Female Runners. Fort Belvoir, VA: Defense Technical Information Center, October 2001. http://dx.doi.org/10.21236/ada400469.
Full textKelsey, Jennifer L. Oral Contraceptives and Bone Health in Female Runners. Fort Belvoir, VA: Defense Technical Information Center, October 2002. http://dx.doi.org/10.21236/ada415838.
Full textKelsey, Jennifer L. Oral Contraceptives and Bone Health in Female Runners. Fort Belvoir, VA: Defense Technical Information Center, October 2003. http://dx.doi.org/10.21236/ada422917.
Full textBurton, Jennifer L., James D. Westervelt, and Stephen Ditchkoff. Simulation of Wild Pig Control via Hunting and Contraceptives. Fort Belvoir, VA: Defense Technical Information Center, October 2013. http://dx.doi.org/10.21236/ada590472.
Full textBiddlecom, Ann, Taylor Riley, Jacqueline E. Darroch, Elizabeth A. Sully, Vladimíra Kantorová, and Mark C. Wheldon. Future Scenarios of Adolescent Contraceptive Use, Cost and Impact in Developing Regions. Guttmacher Institute, August 2018. http://dx.doi.org/10.1363/2018.29732.
Full textRegister, Thomas. Oral Contraceptives Use by Young Women Reduces Peak Bone Mass. Fort Belvoir, VA: Defense Technical Information Center, December 2002. http://dx.doi.org/10.21236/ada417286.
Full textRegister, Thomas. Oral Contraceptives Use by Young Women Reduces Peak Bone Mass. Fort Belvoir, VA: Defense Technical Information Center, September 2000. http://dx.doi.org/10.21236/ada390773.
Full textRegister, Thomas. Oral Contraceptives Use by Young Woman Reduces Peak Bone Mass. Fort Belvoir, VA: Defense Technical Information Center, September 1999. http://dx.doi.org/10.21236/ada376507.
Full text